128 related articles for article (PubMed ID: 12043950)
1. Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity.
O'Neil WM; MacArthur RD; Farrough MJ; Doll MA; Fretland AJ; Hein DW; Crane LR; Svensson CK
J Clin Pharmacol; 2002 Jun; 42(6):613-9. PubMed ID: 12043950
[TBL] [Abstract][Full Text] [Related]
2. Acetylator phenotype prevalence in HIV-infected patients without previous trimethoprim-sulfamethoxazole hypersensitivity.
Quirino T; Bonfanti P; Arcidiacono M; Pusterla L; Cagni A; Scaglione F; Milazzo F
Biomed Pharmacother; 1999 Jun; 53(5-6):286-7. PubMed ID: 10424252
[TBL] [Abstract][Full Text] [Related]
3. Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity.
Alfirevic A; Stalford AC; Vilar FJ; Wilkins EG; Park BK; Pirmohamed M
Br J Clin Pharmacol; 2003 Feb; 55(2):158-65. PubMed ID: 12580987
[TBL] [Abstract][Full Text] [Related]
4. N-acetyltransferase 2 enzyme genotype-phenotype discordances in both HIV-negative and HIV-positive Nigerians.
Kotila OA; Fawole OI; Olopade OI; Ayede AI; Falusi AG; Babalola CP
Pharmacogenet Genomics; 2019 Jul; 29(5):106-113. PubMed ID: 30882558
[TBL] [Abstract][Full Text] [Related]
5. Genotyping of the arylamine N-acetyltransferase polymorphism in the prediction of idiosyncratic reactions to trimethoprim-sulfamethoxazole in infants.
Zielińska E; Niewiarowski W; Bodalski J; Rebowski G; Skretkowicz J; Mianowska K; Sekulska M
Pharm World Sci; 1998 Jun; 20(3):123-30. PubMed ID: 9618736
[TBL] [Abstract][Full Text] [Related]
6. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients.
Carr A; Gross AS; Hoskins JM; Penny R; Cooper DA
AIDS; 1994 Mar; 8(3):333-7. PubMed ID: 8031511
[TBL] [Abstract][Full Text] [Related]
7. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity.
Pirmohamed M; Alfirevic A; Vilar J; Stalford A; Wilkins EG; Sim E; Park BK
Pharmacogenetics; 2000 Nov; 10(8):705-13. PubMed ID: 11186133
[TBL] [Abstract][Full Text] [Related]
8. Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype.
O'Neil WM; Drobitch RK; MacArthur RD; Farrough MJ; Doll MA; Fretland AJ; Hein DW; Crane LR; Svensson CK
Pharmacogenetics; 2000 Mar; 10(2):171-82. PubMed ID: 10762005
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS.
Wolkenstein P; Loriot MA; Aractingi S; Cabelguenne A; Beaune P; Chosidow O
Pharmacogenetics; 2000 Dec; 10(9):821-8. PubMed ID: 11191886
[TBL] [Abstract][Full Text] [Related]
10. N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus.
Kaufmann GR; Wenk M; Taeschner W; Peterli B; Gyr K; Meyer UA; Haefeli WE
Clin Pharmacol Ther; 1996 Jul; 60(1):62-7. PubMed ID: 8689813
[TBL] [Abstract][Full Text] [Related]
11. N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease.
Chen M; Xia B; Chen B; Guo Q; Li J; Ye M; Hu Z
Can J Gastroenterol; 2007 Mar; 21(3):155-8. PubMed ID: 17377643
[TBL] [Abstract][Full Text] [Related]
12. Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders.
Hirvonen A; Saarikoski ST; Linnainmaa K; Koskinen K; Husgafvel-Pursiainen K; Mattson K; Vainio H
J Natl Cancer Inst; 1996 Dec; 88(24):1853-6. PubMed ID: 8961976
[TBL] [Abstract][Full Text] [Related]
13. The arylamine N-acetyltransferase (NAT2) polymorphism and the risk of adverse reactions to co-trimoxazole in children.
Zielińska E; Niewiarowski W; Bodalski J
Eur J Clin Pharmacol; 1998; 54(9-10):779-85. PubMed ID: 9923584
[TBL] [Abstract][Full Text] [Related]
14. N-acetyltransferase 2 acetylation polymorphism: prevalence of slow acetylators does not differ between atopic dermatitis patients and healthy subjects.
Brocvielle H; Muret P; Goydadin AC; Boone P; Broly F; Kantelip JP; Humbert P
Skin Pharmacol Appl Skin Physiol; 2003; 16(6):386-92. PubMed ID: 14528063
[TBL] [Abstract][Full Text] [Related]
15. Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients.
Kagaya H; Miura M; Niioka T; Saito M; Numakura K; Habuchi T; Satoh S
Antimicrob Agents Chemother; 2012 Feb; 56(2):825-9. PubMed ID: 22106207
[TBL] [Abstract][Full Text] [Related]
16. Cigarette smoking, N-acetyltransferase 2 polymorphisms and systemic lupus erythematosus in a Japanese population.
Kiyohara C; Washio M; Horiuchi T; Tada Y; Asami T; Ide S; Takahashi H; Kobashi G;
Lupus; 2009 Jun; 18(7):630-8. PubMed ID: 19433464
[TBL] [Abstract][Full Text] [Related]
17. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions.
Rieder MJ; Shear NH; Kanee A; Tang BK; Spielberg SP
Clin Pharmacol Ther; 1991 Jan; 49(1):13-7. PubMed ID: 1988235
[TBL] [Abstract][Full Text] [Related]
18. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
Okkels H; Sigsgaard T; Wolf H; Autrup H
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
[TBL] [Abstract][Full Text] [Related]
19. N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism.
Spielberg SP
J Pharmacokinet Biopharm; 1996 Oct; 24(5):509-19. PubMed ID: 9131488
[TBL] [Abstract][Full Text] [Related]
20. Strong association between N-acetyltransferase 2 genotype and PD in Hong Kong Chinese.
Chan DK; Lam MK; Wong R; Hung WT; Wilcken DE
Neurology; 2003 Mar; 60(6):1002-5. PubMed ID: 12654968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
